Introduction And Pathogenesis
Hemophagocytic Lymphohistiocytosis (HLH) represents an aggressive, potentially fatal syndrome resulting from inappropriate, prolonged activation of lymphocytes and macrophages.
- Cellular Origin: Driven by abnormalities in T-lymphocytes and Natural Killer (NK) cells.
- Pathophysiology: Defective function of NK and cytotoxic T-cells prevents target cell killing. Causes massive expansion of antigen-specific CD8+ T-lymphocytes.
- Cytokine Storm: Hyperactivated effector cells induce excessive macrophage activation and massive production of proinflammatory cytokines (Interferon-gamma, Tumor Necrosis Factor-alpha, Interleukin-6).
- Hemophagocytosis: Activated macrophages spontaneously phagocytose blood elements (erythrocytes, platelets, leukocytes).
- Tissue Infiltration: Hyperactivated lymphocytes and macrophages infiltrate organs, culminating in extensive tissue necrosis and multiorgan failure.
- Immunophenotype: Phagocytic macrophages express CD163 positivity. Characteristically lack Birbeck granules, CD1a, and CD207 (langerin) positivity.
Etiological Classification
Divided clinically into primary (familial) and secondary (acquired) forms, though significant clinical and genetic overlap exists.
Primary (Familial) Hemophagocytic Lymphohistiocytosis (FHLH)
- Autosomal recessive inheritance; represents ~25% of HLH cases.
- Characterized by genetic mutations affecting cytotoxic granule formation, priming, docking, or fusion.
| Subtype | Gene Mutation | Defective Protein / Function | Unique Clinical Features |
|---|---|---|---|
| FHLH-2 | PRF1 | Perforin / Cytotoxicity, pore formation | High incidence in African descent. |
| FHLH-3 | UNC13D | Munc13-4 / Vesicle priming | Increased incidence of CNS involvement. |
| FHLH-4 | STX11 | Syntaxin / Vesicle fusion | Mild recurrent HLH, colitis. |
| FHLH-5 | STXBP2 | Syntaxin-binding protein 2 | Colitis, hypogammaglobulinemia. |
| Griscelli Syndrome (Type 2) | RAB27A | Rab27A / Vesicle docking | Partial albinism, silver-gray hair. |
| Chediak-Higashi Syndrome | LYST | Lyst / Heterogeneous NK defects | Partial albinism, bleeding tendency, infections. |
| X-Linked Lymphoproliferative (XLP1) | SH2D1A | SAP / Signaling in NK and T-cells | Hypogammaglobulinemia, lymphoma. |
Secondary (Acquired) Hemophagocytic Lymphohistiocytosis
Triggered by separate pathologic processes inducing overwhelming immune activation.
| Trigger Category | Specific Associations |
|---|---|
| Infections | Epstein-Barr Virus (EBV), Cytomegalovirus (CMV), Human Herpesvirus 6 (HHV6), HIV, Adenovirus, Dengue, Influenza, Parvovirus B19, Fungal, Parasitic. |
| Rheumatologic / Autoimmune | Systemic Juvenile Idiopathic Arthritis (termed Macrophage Activation Syndrome), Systemic Lupus Erythematosus, Kawasaki disease. |
| Malignancy | Leukemia, Lymphoma. |
| Immunodeficiency | Severe Combined Immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome, Chronic Granulomatous Disease. |
Clinical Manifestations
Clinical presentation is typically severe and acute, mimicking hyperferritinemic septic shock.
- Systemic Features: Fever (90-100%), weight loss, irritability.
- Reticuloendothelial: Splenomegaly (84-100%), hepatomegaly (70-100%), lymphadenopathy (20-50%).
- Dermatologic: Maculopapular and/or petechial rash (10-60%).
- Pulmonary: Respiratory distress (40-90%), acute respiratory distress syndrome (ARDS).
- Hepatic/Hematologic: Jaundice, liver failure, pancytopenia, bleeding, coagulopathy.
- Central Nervous System (50%): Seizures, ataxia, altered mental status, coma, cranial nerve palsies.
- Isolated CNS HLH: Neuroinflammatory disease occasionally presents without systemic cytopenias or splenomegaly, delaying diagnosis.
Diagnostic Criteria (HLH-2004)
Diagnosis requires either a confirmed molecular genetic defect OR fulfillment of at least 5 of the 8 clinical criteria.
| Criterion | Diagnostic Threshold / Manifestation | Clinical Nuance |
|---|---|---|
| 1. Fever | 38.3°C | Nearly universal in untreated HLH. |
| 2. Splenomegaly | Palpable spleen | Very common; lymphadenopathy is less frequent. |
| 3. Cytopenias | Affecting 2 lineages:- Hemoglobin <9 g/dL (Infants <4 wk: <10 g/dL)- Platelets <100 10/mcL- Neutrophils <1 10/mcL | Ubiquitous. Absence of cytopenias suggests isolated CNS disease or alternative diagnosis. |
| 4. Biochemical | Hypertriglyceridemia (>265 mg/dL) AND/OR Hypofibrinogenemia (<150 mg/dL) | Low fibrinogen in context of severe inflammation is paradoxical and distinctive. |
| 5. Hemophagocytosis | Evident in bone marrow, spleen, lymph nodes, or liver | Not specific to HLH; often not evident early in disease course. |
| 6. NK-Cell Activity | Low or absent | Modern assays measuring perforin degranulation preferred. |
| 7. Ferritin | >500 ng/mL | Most patients present with levels significantly higher (often >10,000 ng/mL). |
| 8. Soluble CD25 | >2400 units/mL (Soluble IL-2 receptor ) | Extremely informative marker of T-cell driven disease and therapy response. |
Differential Diagnosis
| Disease Entity | Differentiating Features |
|---|---|
| Langerhans Cell Histiocytosis (LCH) | Identifiable by CD1a and CD207 (langerin) positivity. Presence of Birbeck granules on electron microscopy. Characterized by lytic bone lesions, seborrheic rash. |
| Juvenile Myelomonocytic Leukemia (JMML) | Marked absolute monocytosis (>1000/mm). Bone marrow lacks hemophagocytosis. Demonstrates GM-CSF hypersensitivity in colony assays. |
| Severe Sepsis / Viral Illness | May trigger secondary HLH, but isolated sepsis lacks extreme hyperferritinemia (>10,000), profound hypofibrinogenemia, or absent NK cell activity. |
Management And Prognosis
Pharmacologic Therapy
Immediate initiation of therapy is mandatory; primary HLH is universally fatal without treatment. Pancytopenia and active infection are NOT contraindications to cytotoxic therapy, as treatment arrests the underlying cytokine storm.
- Standard Regimen: 8-week induction comprising Etoposide, Dexamethasone, and Cyclosporine.
- Intrathecal Therapy: Intrathecal Methotrexate utilized for CNS involvement.
- Mechanism of Etoposide: Exerts direct cytotoxic effect on activated macrophages, interrupting cytokine production and halting the hemophagocytic process.
- Targeted Biologicals:
- Emapalumab: Monoclonal antibody targeting Interferon-gamma. Approved for recurrent, refractory, or progressive primary HLH.
- Anakinra / Ruxolitinib: Interleukin-1 receptor antagonists and JAK inhibitors utilized effectively in secondary HLH or Macrophage Activation Syndrome.
- Supportive Care: Antithymocyte globulin (ATG), broad-spectrum antimicrobials, packed red cells, and platelet transfusions.
Definitive Therapy And Secondary Management
- Hematopoietic Stem Cell Transplantation (HSCT): The only known curative modality for primary (familial) HLH. Achieves long-term cure in >60% of patients. Therapy bridges patients to HSCT.
- Secondary HLH Management: Requires aggressive identification and targeted treatment of the underlying trigger (e.g., antiviral therapy for EBV/CMV, chemotherapy for occult malignancy). Treating the trigger alongside supportive care may yield complete resolution without HSCT.